For example, the small-molecule antagonists, SCH-527123 and SCH-479833, that target CXCR2/CXCR1 were found to inhibit colon cancer and melanoma by decreasing neovascularization and increasing apoptosis of tumor cells [72,73]. Here, CXCR1 is linked to melanoma.